Clearmind Medicine (NASDAQ:CMND) & Relmada Therapeutics (NASDAQ:RLMD) Critical Comparison
MarketBeat compared Relmada Therapeutics (NASDAQ:RLMD) and Clearmind Medicine (NASDAQ:CMND). RLMD has a consensus target price of $12.00 (67.95% upside) versus CMND’s lower outlook, and RLMD is trading at a lower P/E. Institutional ownership is 45.2% for RLMD and 96.1% for CMND; beta is 0.43 for RLMD and 0.87 for CMND.
How this was made
The 30-second read
Why it matters
Because it does not report new clinical results, regulatory actions, financing, or corporate transactions, the trading impact is mainly sentiment/relative-ranking rather than a fundamental re-rate catalyst.
Market read
Traders may use the comparative analyst-target framing for relative positioning between RLMD and CMND, but there is no new company-specific catalyst.
What to watch
Key missing drivers are trial readouts, enrollment/timeline changes, cash runway, and dilution risk—ownership/valuation comparisons don’t substitute for those.
Background
The article is a side-by-side comparison of Relmada Therapeutics (RLMD) and Clearmind Medicine (CMND) across analyst targets, valuation, institutional/insider ownership, and basic risk/profitability metrics.
Ticker impact
Article compares RLMD vs CMND and cites RLMD’s higher consensus analyst rating and $12.00 target implying 67.95% upside.
Low-to-moderate near-term support if traders treat the target as fresh sentiment; otherwise limited follow-through.
The piece is a comparative recap of ratings/valuation/ownership rather than a drug-result, financing, or corporate action update.
Article compares CMND vs RLMD and highlights CMND’s weaker consensus rating and higher valuation metrics relative to RLMD.
Mild downside bias versus RLMD if the market anchors to the comparative analyst view; limited absolute impact.
No new clinical, regulatory, or financial datapoint is provided—only comparative metrics and targets.
Market effects
Reinforces that sentiment/targets for small-cap CNS/psychedelic biotechs are being traded as relative value, not on new trial outcomes.
None specific; both are US-listed small caps.
Limited; no cross-border deal/regulatory action mentioned.
Counterpoint
Analyst target/upside claims may be stale or already priced; without new trial/financing/regulatory news, the comparison is unlikely to drive sustained repricing.
Key entities
- companyRelmada Therapeutics
Clinical-stage biotech with a phase 3 major depressive disorder program for esmethadone (per article background).
- companyClearmind Medicine
Clinical pharmaceutical biotech focused on psychedelic medicines; MEAI IND-enabling and pre-clinical obesity/metabolic work (per article background).
